Background: There is considerable practice variation in labelling, diagnosis and treatment of adults with sterile bone inflammation. We developed a expert consensus recommendations on the disease definition, diagnosis and treatment of this rare condition.
Methods: Systematic literature review and Grading of Recommendations, Assessment, Development and Evaluations-based appraisal of evidence, two Delphi surveys and three digital and in-person consensus meetings with a multidisciplinary expert panel and patient representatives.
Results: A consensus disease definition was developed and the term 'chronic non-bacterial osteitis' (CNO) is proposed to describe adults with sterile bone inflammation. For initial imaging evaluation of adults with suspected CNO, the panel recommends MRI or otherwise CT combined with nuclear imaging. Whole-body imaging at initial evaluation can be considered for diagnostic and prognostic purposes. Suggested first-line treatment in adults with active CNO includes nonsteroidal anti-inflammatory drugs/cyclooxygenase 2-inhibitors. Second-line treatment preferably consists of intravenous bisphosphonates, and otherwise tumour necrosis factor-α inhibitors. Choice between them should be individualised, considering the presence of additional inflammatory features. The panel further discusses outcome measures, follow-up and management of adverse events and complications.
Conclusions And Future Perspectives: These expert consensus recommendations are intended to support healthcare professionals worldwide in their care for adults with CNO. They also lay the groundwork for establishing international patient registries, translational research lines and multicentre trials, all of which are urgently required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/ard-2024-226446 | DOI Listing |
United European Gastroenterol J
March 2025
University Hospital RWTH Aachen, Aachen, Germany.
Background And Aims: The severe alpha-1 antitrypsin deficiency (AATD) genotype Pi*ZZ increases the risk of liver disease (AATD-LD) and lung disease. While non-invasive tests (NITs) are widely used for fibrosis stage and monitoring of all liver diseases, the consensus for use in AATD-LD is limited. A Delphi panel study was conducted to address this need.
View Article and Find Full Text PDFClin Transl Oncol
March 2025
Pathology Department, Hospital del Mar, Pompeu Fabra University, Hospital del Mar Research Institute, Barcelona, Spain.
Gastroesophageal carcinomas, including gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC), pose a global health challenge due to their heterogeneity. The approach to diagnosis and treatment should first differentiate between GEA and ESCC. Over the past decade, therapies for metastatic or advanced GEA/ESCC have expanded, with several new therapeutic targets alongside trastuzumab for metastatic HER2-positive GEA.
View Article and Find Full Text PDFActa Neurochir (Wien)
March 2025
Department of Neurosurgery, Aalborg University Hospital, Aalborg, Denmark.
Background: Multimodal neuromonitoring (MMM) aids early detection of secondary brain injury in neurointensive care and facilitates research in pathophysiologic mechanisms of the injured brain. Invasive ICP monitoring has been the gold standard for decades, however additional methods exist (aMMM). It was hypothesized that local practices regarding aMMM vary considerably and that inter-and intracenter consensus is low.
View Article and Find Full Text PDFInt J Surg
March 2025
Department of Digestive and Emergency Surgery, "S.Maria" Hospital, Terni, Italy.
Background: The management of high-surgical risk patients with moderate to severe acute cholecystitis is challenging in clinical practice. Early laparoscopic cholecystectomy is considered the gold standard for patients who do not respond to conservative treatment. However, for those unfit for surgery due to high-surgical risk, alternative treatment options such as percutaneous cholecystostomy (PC) are available.
View Article and Find Full Text PDFSex Med Rev
March 2025
Department of Urology, University of Texas MD Anderson Cancer Center and McGovern Medical School at Houston, Houston, 77030, TX, United States.
Introduction: Penile prosthesis (PP) is one of the main approved therapies for erectile dysfunction (ED). Greater than 50 years of clinical use has led to considerable innovation in PP surgery and patient care.
Objectives: To summarize the current literature and provide updated clinical evidence to inform healthcare providers on best practices with PP.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!